GP
Additional lines of treatment (high cost drugs)
You are here : Home > Formulary Search > Additional lines of treatment (high cost drugs)
Documentation
Guidelines (National)
Drugs
Below are listed all drugs that are used to treat Additional lines of treatment (high cost drugs) .
- No records returned.
Committee Recommendations (2)
The Surrey Heartlands Integrated Care System Area Prescribing Committee agreed an updated version of the Standard Operating Process (SOP).
See additional documentation section.
The Surrey Heartlands ICS Area Prescribing Committee (APC) has agreed an additional lines of treatment process and principles in conjunction with the local Rheumatology, Gastroenterology and Dermatology Clinical Networks.
Guideline Profile
Indication :
Additional lines of treatment (high cost drugs)
Keywords :
Biologic, NICE, JAK, Cytokine modulator, immunosuppressant, monoclonal antibody, biosimilar, TNF Alpha Inhibitor, DMARD, bDmard, Disease modulating, csDMARD, conventional synthetic, targeted synthetic, tsDMARD, 4th line
RA (severe), RA (moderate), AS, NrSpA, PsA, Crohn's, UC, IBD, Psoriasis, Rheumatology, Dermatology, ankylosing spondylitis, non-radiographic spondyloarthritis, rheumatoid arthritis, ulcerative colitis, interleukin, IL-6, janus kinase inhibitor, sequential, additional, vedolizumab, adalimumab, infliximab, ustekinumab, etanercept, golimumab, guselkumab, tocolizumab, rituximab, ixekizumab, secukinumab, baracitinib, upadacitinib, certolizumab, filgotinib, sarilumab, apremilast, bimekizumab, brodalumab, dimethyl fumarate, risankizumab, tildrakizumab
Brand Names Include :
Important Information :
Latest Additions Date From :
Latest Additions Date To :
Supporting Documents :
3